Moomoo AI 已提取核心信息
On February 28, 2024, Novavax, Inc. reported its financial results for the fourth quarter and full year of 2023. The company announced Q4 revenues of $291 million and full-year revenues of $1.0 billion. Novavax also provided guidance for 2024, projecting total revenues between $800 million to $1 billion. The company has made significant strides in reducing operating expenses by 41% compared to 2022 and has reduced its workforce by 30% since Q1 2023. Novavax settled with Gavi regarding a 2021 advance purchase agreement, which has removed financial uncertainty. The company is progressing with its Phase 3 COVID-19-Influenza Combination vaccine trial, expected to begin in the second half of 2024, with a potential launch in 2026. Novavax's net loss for Q4 was $178 million, an improvement over the $182 million loss in the same period the previous year. The company ended the year with $584 million in cash and cash equivalents.
On February 28, 2024, Novavax, Inc. reported its financial results for the fourth quarter and full year of 2023. The company announced Q4 revenues of $291 million and full-year revenues of $1.0 billion. Novavax also provided guidance for 2024, projecting total revenues between $800 million to $1 billion. The company has made significant strides in reducing operating expenses by 41% compared to 2022 and has reduced its workforce by 30% since Q1 2023. Novavax settled with Gavi regarding a 2021 advance purchase agreement, which has removed financial uncertainty. The company is progressing with its Phase 3 COVID-19-Influenza Combination vaccine trial, expected to begin in the second half of 2024, with a potential launch in 2026. Novavax's net loss for Q4 was $178 million, an improvement over the $182 million loss in the same period the previous year. The company ended the year with $584 million in cash and cash equivalents.
2024年2月28日，Novavax, Inc.公布了其2023年第四季度和全年财务业绩。该公司宣布第四季度收入为2.91亿美元，全年收入为10亿美元。Novavax还提供了2024年的指导方针，预计总收入在8亿美元至10亿美元之间。与2022年相比，该公司在将运营支出减少41％方面取得了长足的进步，并且自2023年第一季度以来裁员了30％。Novavax与Gavi就2021年的预购协议达成和解，该协议消除了财务不确定性。该公司的3期COVID-19流感联合疫苗试验正在取得进展，该试验预计将于2024年下半年开始，并可能在2026年启动。Novavax第四季度的净亏损为1.78亿美元，比去年同期的1.82亿美元亏损有所改善。该公司在年底拥有5.84亿美元的现金和现金等价物。
2024年2月28日，Novavax, Inc.公布了其2023年第四季度和全年财务业绩。该公司宣布第四季度收入为2.91亿美元，全年收入为10亿美元。Novavax还提供了2024年的指导方针，预计总收入在8亿美元至10亿美元之间。与2022年相比，该公司在将运营支出减少41％方面取得了长足的进步，并且自2023年第一季度以来裁员了30％。Novavax与Gavi就2021年的预购协议达成和解，该协议消除了财务不确定性。该公司的3期COVID-19流感联合疫苗试验正在取得进展，该试验预计将于2024年下半年开始，并可能在2026年启动。Novavax第四季度的净亏损为1.78亿美元，比去年同期的1.82亿美元亏损有所改善。该公司在年底拥有5.84亿美元的现金和现金等价物。
有用
没用